Development of SARS-COV therapeutics using quaternary protein mimetics
SARS-CoV, a novel virus belonging to group IV coronavirus, was discovered in association with cases of severe acute respiratory syndrome (SARS) in 2003. The spike (S) protein of SARS-CoV is responsible for receptor binding and membrane fusion. The MPER, the Trp-rich membrane proximal external region...
Saved in:
Main Author: | Neo, Tuan Ling |
---|---|
Other Authors: | James P. Tam |
Format: | Theses and Dissertations |
Language: | English |
Published: |
2010
|
Subjects: | |
Online Access: | https://hdl.handle.net/10356/41875 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Nanyang Technological University |
Language: | English |
Similar Items
-
Study of sars-cov entry mechanism and development of protein mimetic inhibitors
by: Ji, Zhe
Published: (2011) -
Interaction of SARS-CoV spike protein with lipid rafts of host cells during viral entry
by: Lu, Yanning
Published: (2008) -
Examining the immunoreactivities of the receptor-binding domain of SARS-CoV-2 spike proteins using a panel of human monoclonal antibodies
by: Tan, Jie Ling
Published: (2022) -
Development of human monoclonal antibodies against SARS-CoV-2
by: Wong, Joel Xu En
Published: (2021) -
Structural and functional characterization of SARS coronavirus envelope protein E.
by: Parthasarathy Krupakar.
Published: (2011)